Guide to oral anticoagulant therapy (Part I) Italian federation of anticoagulant clinics;Guide sur le traitement anticoagulant par voie orale (1(re) partie)

Sang Thrombose Vaisseaux

Volumn 10, Issue 5, 1998, Pages 291-313

  Boneu, Bernard ^a   Schved, Jean François ^b  

^a CHU PURPAN   (France)

^b HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; COLESTIPOL; COLESTYRAMINE; DANAZOL; DIPYRIDAMOLE; GASTROINTESTINAL AGENT; GLIBENCLAMIDE; GLUCAGON; GRISEOFULVIN; HEPARIN; KETOCONAZOLE; MAGNESIUM TRISILICATE; MERCAPTOPURINE; METHOTREXATE; METOPROLOL; MITOTANE; NALIDIXIC ACID; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHENFORMIN; QUININE; STREPTOKINASE; TAMOXIFEN; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; ARTERY DISEASE; ARTERY THROMBOSIS; ARTICLE; BIOPROSTHESIS; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG MECHANISM; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART DILATATION; HEART INFARCTION; HEART VALVE PROSTHESIS; HUMAN; INTRACARDIAC THROMBOSIS; LUNG EMBOLISM; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PATIENT EDUCATION; PRACTICE GUIDELINE; VALVULOPLASTY;

EID: 0031826624     PISSN: 09997385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991 ; 324 : 1865-75.
2. Suttie JW, Vitamin K antagonists. In : Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis. Philadelphia : JB Lippmcott Company, 1994 : 1565.
3. Thijsen HHW, Hamulyak K, Willigers H. 4-Hydroxycoumarin oral anticoagulants : pharmatokinetics-response relationships. Thromb Haemostas 1988 ; 60 : 35-8.
4. Cannegieter SC, Rosendaal FR, Wintzen AR, van den Meer FJM, Vandenbroucke JP, Briet E, Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995 ; 333 : 11-7.
5. Stein PD, Alpert JS, Copeland T, Dalen JE, Goldman S, Turpie AGG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1992a ; 102 (suppl. 4) : S445-55.
6. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 2 : oral anticoagulants. Circulation 1994a ; 89 : 1469-80.
7. Van den Besselaar ANPH, van den Meer FJM, Gerrits-Drabbe CW. Therapeutic control of oral anticoagulant treatment in the Netherlands. Am J Clin Pathol 1988 ; 90: 685-90.
8. Israel DH, Samm KS, Fuster V. Antithrombotic therapy in prosthetic valve replacement. Am Heart J 1994 ; 127 : 400-11.
9. BCSH Haemobtasis and Thrombosis Task Force of the British Society for Haematology. Guidelines on oral anticoagulation : second edition. J Clin Pathol 1990 ; 43 : 177-83.
10. Turpie AGG, Gunstensen J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valves replacement. Lancet 1988 ; i : 1242-5.
11. Becker RC, Ansell J. Antithrombotic therapy. Arch Intern Med 1995 ; 155 . 149-61.
12. Levine HJ, Pauker SG, Salzman EW, Eckman MH. Antithrombotic therapy in valvular heart disease. Chest 1992 ; 102 (suppl. 4) : S434-54.
13. Petersen P, Boysen G, Godtfredsen J, Andersen B. Placebo controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation : the Copenhagen AFASAK study. Lancet 1989 ; i : 175-9.
14. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non rheumatic atrial fibrillation. N Engl J Med 1990 ; 323 : 1505-11.
15. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation : Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994 ; 343 . 687-91.
16. Connoly JS, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. Circulation 1991 ; 83 : 349-55.
17. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991 ; 84 : 527-39.
18. Laupacis A, Albers GW, Dunn M, Feigerg W. Antithrombotic therapy in atrial fibrillation. Chest 1992 ; 102 (suppl. 4) : S426-33.
19. Laupacis A, Albers GW, Dalen J, Dunn M, Feigerg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest 1995 ; 108 (suppl. 4) : S352-9.
20. European Atrial Fibrillation Trial Study Group, Secondary prevention in non rheumatic atrial fibrillation after transient ischaemic attack or minor stoke. Lancet 1993 ; 342 : 1255-62.
21. Albers GW. Atrial fibrillation and stroke. Three new studies, three remaining questions. Arch Intern Med 1994 ; 154 : 1443-8.
22. Cheng JW, Spingler SA. Should all patients with dilated cardiomyopathy receive chronic anticoagulation ? Ann Pharmacother 1994 ; 28 : 604-9.
23. Sixty Plus Reinfarction Group. A double blind trial to assess long-term oral anticoagulant therapy in the elderly patients after myocardial infarction Lancet 1980 ; ii : 989-94.
24. Smith P, Amesen H, Holme I. The effect of warfarin on mortality and reintarction after myocardial infarction. N Engl J Med 1990 ; 323 . 147-52.
25. Anticoagulants in Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994 ; 343 : 499-503.
26. Cairns JA. Oral anticoagulants or aspirin after myocardial infarction ? Lancet 1994 ; 343 : 497-8.
27. Neri Serneri GG, Rovelli F, Gensini GF, Pirelli S, Carnovali M, Fortini A. Effectiveness of low dose heparin for prevention of myocardial infarction Lancet 1987 ; i : 937-42.
28. Cairns JA, Hirsh J, Lewis HD Jr. Resnekov L, Théroux P. Antithrombotic agents in coronary artery disease. Chest 1992 ; 102 (suppl. 4) . S456-81.
29. Stein PD, Dalen JE, Goldman S, Schwartz L, Turpie AGG, Théroux P. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass graft follow ins PTCA Chest 1992b ; 102 (suppl. 4) : S507-15.
30. Van den Meer J, Hillige HL, Kootstra GJ, et al. for the CABADAS research group. Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery : a comparison of low-dose aspirin plus dipyridamole, and oral anticoagulants. Lancet 1993 ; 342 : 257-64.
31. Taberner DA, Poller L, Burslem RW, Jones JB. Oral anticoagulant controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis. Br Med J 1978 ; 1 : 272-4.
32. Francis CW, Marder VJ, Evarts CM, Yaukoolbodi S. Two-step warfarin therapy : prevention of postoperative venous thrombosis without excessive bleeding. JAMA 1983 ; 249 : 374-8.
33. Poller L, McKernan A, Thomson JM. et al. Fixed minidose warfarin : a new approach to prophylaxis against venous thrombosis after major surgery. Br Med J 1987 ; 295 : 1309-12.
34. Powers PJ. Gent M. Jay RM, et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fracturated hip Arch Intern Med 1989 ; 149 : 771-4.
35. Hull RD, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis N Engl J Med 1979 ; 302 . 855-8
36. Hull RD, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982 ; 306 : 189-94.
37. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy : a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis Thromb Haemost 1995 ; 74 : 606-11.
38. Kamashta MA, Cuadrado MJ, Mujic F, et al. Management of thrombosis in the antiphospholipid antibody syndrome. N Engl Med J 1995 ; 332 : 993-8.
39. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension : natural history and the importance of thrombosis. Circulation 1984 ; 70 : 580-7.
40. Sherman DG, Dyken ML, Gent M, et al. Antithrombotic therapy for cerebrovascular disorders. An update. Chest 1995 ; 108 (suppl. 4) : S4440-56.
41. Sherman DG, Dyken ML, Fisher M, et al. Antithrombotic therapy for cerebrovascular disorders. Chest 1989 ; 95 (suppl.) : S140-55.
42. Kretschmer G, Wenzl E, Schemper M. et al. Influence of postoperative anticoagulant treatment of patient survival after femoropopliteal vein bypass sursery. Lancet 1988 ; i : 797-8.
43. Poller L. Oral anticoagulant therapy. In : Bloom AL, Thomas DP, eds. Haemosiasis and thrombosis. Edimburgh : Churchill Living-stone, 1987. 870-85.
44. Samama M Controindicazioni ed effetti avversi della terapia anticoagulante orale (TAO) : aspetti clinici e biologici. In : Coccheri S, Palareti G, eds. La terapia anticoagulante orale : teoria e prarica. Ferro Ediziom, 1992 157-70.
45. Ginsberg JS, Hirsh J, Turner DC, Levine MK, Burrows R. Risk to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989 ; 61 : 197-203.
46. Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1992 ; 102 (suppl 4) : S385-90.
47. Rodeghiero F, Castaman G. La piastrinopenia da eparina. Atti del 35° Congresso Nazionale SIE 1995 : 141-8.
48. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children : first analyses of the Canadian Registry of VTE. Blood 1994a ; 83 : 1251-7.
49. Andrew M, Marzinotto V, Brooker LA, et al. Oral anticoagulation therapy in pediatric patients . a prospective study. Thromb Haemost 1994b ; 71 . 265-9.
50. Bejth RJ, Landefeld CS. Anticoagulants in older patients : a safety perspective Drugs & Aging 1995 ; 6 : 45-54.
51. Palareti G, Leali N, Coccheri S, et al. on behalf of the ISCOAT (Italian Study on Complications of Oral Anticoagulant Therapy) Study Group. Bleeding complications of oral anticoagulant treatment : an inception-cohort, prospective, collaborative study (ISCOAT). Lancet 1996 ; 348 . 423-8
52. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993 ; 153 : 1665-70.
53. Broekmans AW, Bertina RM, Loeliger EA, Hofmann V, Klingemann HG. Protein C and the development of skin necrosis during anticoagulant therapy. Thromb Haemost 1983 ; 49 . 244-51.
54. Hirsh J, Faster V. Guide to anticoagulant therapy. Part I : Heparin Circulation 1994b ; 89 . 1449-68
55. Fennerty A, Dolben J, Thomas P, et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J 1984 ; 288 : 1268-70.
56. Gallus A, Jackaman J, Tillet J, Mills W, Wycherley A, Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancer 1986 ; ii : 1293-6.
57. Hull RD, Raskob GE, Rosenbloom, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990 ; 322 : 1260-4.
58. Cosgrif, Stuart W. Chronic anticoagulant therapy in recurrent embolism of cardial origin. Ann Int Med 1953 ; 38 : 278-87.
59. Wright IS. Treatment of thromboembolic disease. JAMA 1960 ; 174 : 1921-4.
60. Poller L, Thomson J. Evidence for rebound hypercoagulabaility after stopping anticoagulants. Lancet 1964 ; ii : 62-4.
61. Poller L, Thomson J. Reduction of "rebound" hypercoagulability by gradual withdrawal ("tailing off') of oral anticoagulants. Br Med J 1965 ; 1 : 1476-7.
62. Harenberg J, Haas R, Zimmermann R. Plasma hypercoagulability after termination of oral anticoagulants. Thromb Res 1983. 29 627-33
63. Schofleid KP, Thomson JM, Poller L. Protein C response to induction and withdrawal of oral anticoagulant treatment. Clin Lab Haemat 1987 ; 9 : 255-62.
64. Grip L, Blomback M, Schulman S. Hypercoagulable state and thromboembolism following warfarin withdrawal in post-myocardial-infarction patients. Eur Heart J 1991 ; 12 : 1225-33.
65. Raskob GE, Dunca SS, Morrissey JH, et al. Effect of treatment with low-dose warfarinaspirin on activated factor VII. Blood 1995 ; 85 : 3034-9.
66. Palareti G, Legnani C, Guazzaloca G, et al. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants : a prospective study. Thromb Haemost 1994 ; 72 . 222-6.
67. Palareti G, Legnani C, Frascaro M, Guazzaloca G, Coccheri S, Factor VIII : C levels during oral anticoagulation and after its withdrawal. Thromb Haemost 1995 ; 74 : 1609-10.
68. Gurwitz JH, Avorn J, Ross-Degnan D. Age-related changes in warfarin pharmaeodynamics. Clin Pharmacol Therapeutics 1991 ; 49 : 166-70.
69. Dobrzanski S, Duncan SE, Harkiss A, Wardlaw A. Age and weight as determinants of warfarin requirements. Clin Hasp Pharmacy 1993 ; 8 : 75-7.
70. Poller L, Taberner DA. Dosage and control of oral anticoagulants : an international collaborative study. Br J Haematol 1982 ; 51 : 479-85
71. Kalra PA, Cooklin M, Wood G, O'Shea GM, Holmes AM. Dietary modification as cause of anticoagulation instability. Lancet 1988 ; ii : 803 (letter).
72. Robinson A, Liau FO, Routledge PA, Backhouse G, Spragg BP, Bentley DP. Lipids and warfarin requirements. Thromb Haemost 1990 ; 63 : 148-9.
73. O'Reilly RA, Aggeler PM, Hoag MS, Leong LS, Kropatkin ML. Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs. The first reported kindred. N Engl J Med 1964 ; 271 : 809-15.
74. O'Reilly RA. The second reported kindred with hereditary resistance to oral anticoagulant drugs. N Engl J Med 1970 ; 282 : 1448-51.
75. Alving BM, Strickler MP, Knight RD, Ban CF, Berenberg JL, Peck CC. Hereditary warfarin resistance. Investigation of a rare phenomenon. Arch Int Med 1985 ; 145 : 499-501.
76. Shearer MJ, Vitamin K. Lancet 1995 ; 343 229-34.
77. Hart JP, Shearer MJ, Klenerman L, et al. Electrochemical detection of depressed circulating levels of vitamin K1 in osteoporosis. J Clin Endocrinol Vetab 1985 . 60 . 1268-9.
78. Knapen MH, Hamulya K, Vermeer C. The effect of vitamin K supplementation on circulating osteocalcin (bone gla protein) and unnary calcium. Ann Intem Med 1989 ; 111 : 1001-5.
79. Rosen HN, Maitland LA, Suttie HW, Manning WJ, Glynn RJ, Greenspan SL. Vitamin-K and maintenance of skeletal integrity in adults. Am J Med 1993 . 94 : 62-8.
80. Fiore CE, Tamburino C, Forti R, et al. Reduced bone mineral content in patients taking an oral anticoagulant. South Med J 1990 ; 83 : 538-42.
81. Kumar S, Haigh JRM, Rhodes LE, et al. Poor compliance is a major factor in unstable outpatient control of anticoagulant therapy. Thromb Haemost 1989 ; 62 : 729-32.
82. Kempin SG. Warfarin resistance caused by broccoli. N Engl J Med 1983 ; 308 . 1229-30.
83. Marongiu F, Sorano GG, Conti M, et al. Known vitamin K intake and management of poorly controlled oral anticoagulant therapy. Lancet 1992 ; 340 : 545-6.
84. Sorano GG, Biondi G, Conti M, et al. Controlled vitamin K content in diet for improving the management of poorly controlled anticoagulated patients : a clinical practice proposal. Haemostasis 1993 ; 23 : 77-82.
85. Manotti C, Quintavalla R, Pattacini C, et al. Seasonal variation of oral anticoagulant effect. Thromb Haemost 1994 ; 71 : 802-3.
86. Lancaster TR, Singer DE, Sheehan MA, et al. The impact of long-term warfarin therapy on quality of life. Arch Intern Med 1991 ; 151 : 1944-9.
87. Freedman MD, Olatidoye AG. Clinically significant drug interaction with the oral anticoagulants Drug Saf 1994 ; 10 : 381-94.
88. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interaction of warfarin with drugs and food. Ann Intern Med 1994 ; 121 : 676-83.
89. Langman MJS, Weil J, Wainwriht P, et al. Risk of bleeding peptic ulcer associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994 ; 343 : 1075-8.
90. Taylor FC, Ramsay ME, Tan G, Gabbay J, Cohen H. Evaluation of patients' knowledge about anticoagulant treatment. Qual Health Care 1994 ; 3 : 79-85.